Escherichia coli Nissle 1917 enhances bioavailability of serotonin in gut tissues through modulation of synthesis and clearance

Accumulating evidence shows indigenous gut microbes can interact with the human host through modulation of serotonin (5-HT) signaling. Here we investigate the impact of the probiotic Escherichia coli Nissle 1917 (EcN) on 5-HT signalling in gut tissues. Ex-vivo mouse ileal tissue sections were treated with either EcN or the human gut commensal MG1655, and effects on levels of 5-HT, precursors, and metabolites, were evaluated using amperometry and high performance liquid chromatography with electrochemical detection (HPLC-EC). Exposure of tissue to EcN cells, but not MG1655 cells, was found to increase levels of extra-cellular 5-HT. These effects were not observed when tissues were treated with cell-free supernatant from bacterial cultures. In contrast, when supernatant recovered from untreated ileal tissue was pre-incubated with EcN, the derivative cell-free supernatant was able to elevate 5-HT overflow when used to treat fresh ileal tissue. Measurement of 5-HT precursors and metabolites indicated EcN also increases intracellular 5-HTP and reduces 5-HIAA. The former pointed to modulation of tryptophan hydroxylase-1 to enhance 5-HT synthesis, while the latter indicates an impact on clearance into enterocytes through SERT. Taken together, these findings show EcN is able to enhance 5-HT bioavailability in ileal tissues through interaction with compounds secreted from host tissues.

[1]  W. Khan,et al.  Serotonin and GI Disorders: An Update on Clinical and Experimental Studies , 2012, Clinical and Translational Gastroenterology.

[2]  H. Bruch,et al.  Cell‐free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[3]  Henry C. Lin,et al.  Using Probiotics in Gastrointestinal Disorders , 2012 .

[4]  S. Raimondi,et al.  Folate Production by Probiotic Bacteria , 2011, Nutrients.

[5]  F. Shanahan,et al.  Probiotics: an emerging therapy. , 2005, Current pharmaceutical design.

[6]  L. Ogilvie,et al.  Dysbiosis modulates capacity for bile acid modification in the gut microbiomes of patients with inflammatory bowel disease: a mechanism and marker of disease? , 2012, Gut.

[7]  A. Wieser,et al.  TcpC protein from E. coli Nissle improves epithelial barrier function involving PKCζ and ERK1/2 signaling in HT-29/B6 cells , 2013, Mucosal Immunology.

[8]  H. Matthes,et al.  Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN) , 2010, BMC complementary and alternative medicine.

[9]  E. Mayer,et al.  Alosetron and irritable bowel syndrome , 2003, Expert opinion on pharmacotherapy.

[10]  B. Leonard.  HPA and Immune Axes in Stress: Involvement of the Serotonergic System , 2007, Neuroimmunomodulation.

[11]  M. Yeoman,et al.  Age-related changes in melatonin release in the murine distal colon. , 2013, ACS chemical neuroscience.

[12]  S. Nuding,et al.  NF-κB- and AP-1-Mediated Induction of Human Beta Defensin-2 in Intestinal Epithelial Cells by Escherichia coli Nissle 1917: a Novel Effect of a Probiotic Bacterium , 2004, Infection and Immunity.

[13]  Colin Hill,et al.  Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome , 2008, Proceedings of the National Academy of Sciences.

[14]  H. Forssberg,et al.  Normal gut microbiota modulates brain development and behavior , 2011, Proceedings of the National Academy of Sciences.

[15]  J. Galligan,et al.  In vitro continuous amperometric monitoring of 5-hydroxytryptamine release from enterochromaffin cells of the guinea pig ileum. , 2007, The Analyst.

[16]  R. Blakely,et al.  A dialogue between the immune system and brain, spoken in the language of serotonin. , 2013, ACS chemical neuroscience.

[17]  M. Bellini,et al.  Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome , 2014, Techniques in Coloproctology.

[18]  M. Stolte,et al.  Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine , 2004, Gut.

[19]  N. W. Davis,et al.  The complete genome sequence of Escherichia coli K-12. , 1997, Science.

[20]  F. Sundler,et al.  Endocrine cells in human intestine: an immunocytochemical study. , 1983, Gastroenterology.

[21]  Michael Camilleri,et al.  Treating irritable bowel syndrome: overview, perspective and future therapies , 2004, British journal of pharmacology.

[22]  Andrew H. Van Benschoten,et al.  Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. , 2014, Cell host & microbe.

[23]  D. Wong,et al.  Serotonin Uptake and Serotonin Uptake Inhibition , 1990, Annals of the New York Academy of Sciences.

[24]  J. Tack,et al.  REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders , 2007 .

[25]  M. Yeoman,et al.  Impaired colonic motility and reduction in tachykinin signalling in the aged mouse , 2014, Experimental Gerontology.

[26]  D. R. Linden,et al.  Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[27]  Mirko Diksic,et al.  Study of the brain serotonergic system with labeled α‐methyl‐l‐tryptophan , 2001 .

[28]  J. Boudeau,et al.  Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent–invasive E. coli strains isolated from patients with Crohn's disease , 2003, Alimentary pharmacology & therapeutics.

[29]  K. Hayes,et al.  The K5 Capsule of Escherichia coli Strain Nissle 1917 Is Important in Mediating Interactions with Intestinal Epithelial Cells and Chemokine Induction , 2009, Infection and Immunity.

[30]  H. Valentin,et al.  Biotechnological production and application of vitamin E: current state and prospects , 2005, Applied Microbiology and Biotechnology.

[31]  V. de Crécy-Lagard,et al.  Comparative genomics of bacterial and plant folate synthesis and salvage: predictions and validations , 2007, BMC Genomics.

[32]  E. Tartour,et al.  [Neuroendocrine tumors]. , 1992, La Revue du praticien.

[33]  R. Ley,et al.  Ecological and Evolutionary Forces Shaping Microbial Diversity in the Human Intestine , 2006, Cell.

[34]  M. Camilleri,et al.  Serotonin: a mediator of the brain–gut connection , 2000, American Journal of Gastroenterology.

[35]  M. Gershon.  Review article: roles played by 5‐hydroxytryptamine in the physiology of the bowel , 1999, Alimentary pharmacology & therapeutics.

[36]  W. R. Wikoff,et al.  Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites , 2009, Proceedings of the National Academy of Sciences.

[37]  R. Sleator.  Bioengineered Bugs begins . . . , 2010 .

[38]  M Diksic,et al.  Study of the brain serotonergic system with labeled α‐methyl‐l‐tryptophan , 2001, Journal of neurochemistry.

[39]  K. Fellermann,et al.  Induction of Human β-Defensin 2 by the Probiotic Escherichia coli Nissle 1917 Is Mediated through Flagellin , 2007, Infection and Immunity.

[40]  J. John Mann,et al.  Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum , 2008, Cell.

[41]  张静,et al.  Banana Ovate family protein MaOFP1 and MADS-box protein MuMADS1 antagonistically regulated banana fruit ripening , 2015 .

[42]  M. Möllenbrink,et al.  [Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor)]. , 1994, Medizinische Klinik.

[43]  M. Crowell,et al.  Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. , 2004, Gastroenterology.

[44]  M. Bader,et al.  A unique central tryptophan hydroxylase isoform. , 2003, Biochemical pharmacology.

[45]  P. Gionchetti,et al.  Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. , 2006, World journal of gastroenterology.

[46]  M. Crowell,et al.  The role of serotonin in the pathophysiology of irritable bowel syndrome. , 2001, The American journal of managed care.

[47]  M. Stolte,et al.  Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis , 1997, Alimentary pharmacology & therapeutics.

[48]  J. Mallet,et al.  Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Henker,et al.  The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers , 2007, European Journal of Pediatrics.

[50]  L. Ogilvie,et al.  Evolutionary, ecological and biotechnological perspectives on plasmids resident in the human gut mobile metagenome , 2012, Bioengineered bugs.

[51]  Rustem F. Ismagilov,et al.  Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis , 2015, Cell.

[52]  V. Geoffroy,et al.  Decreased osteoclastogenesis in serotonin-deficient mice , 2012, Proceedings of the National Academy of Sciences.

[53]  B. Patel,et al.  High performance liquid chromatography method for the detection of released purinergic and biogenic amine signaling molecules from in vitro ileum tissue. , 2010, Journal of separation science.

[54]  Sandeep Kumar,et al.  Disruption of Escherichia coli Nissle 1917 K5 Capsule Biosynthesis, through Loss of Distinct kfi genes, Modulates Interaction with Intestinal Epithelial Cells and Impact on Cell Health , 2015, PloS one.

[55]  U. Sonnenborn,et al.  The non-pathogenic Escherichia coli strain Nissle 1917 – features of a versatile probiotic , 2009 .

[56]  W. Khan.  The Role of 5-HT Dysregulation in Inflammatory Bowel Disease. , 2013, Gastroenterology & hepatology.

[57]  Intracellular and extracellular sampling to monitor the neurotransmission process using a chromatographic method , 2011 .

[58]  M. Wilks.  Bacteria and early human development. , 2007, Early human development.

[59]  F. Shanahan,et al.  Therapeutic implications of manipulating and mining the microbiota , 2009, The Journal of physiology.

[60]  P. Scully,et al.  The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner , 2013, Molecular Psychiatry.

[61]  W. Chey,et al.  Manipulation of the Gut Microbiota as a Novel Treatment Strategy for Gastrointestinal Disorders , 2012 .

[62]  J. Cryan,et al.  The microbiome‐gut‐brain axis: from bowel to behavior , 2011, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[63]  F. Shanahan,et al.  The gut flora as a forgotten organ , 2006, EMBO reports.

[64]  Michael Bader,et al.  Synthesis of Serotonin by a Second Tryptophan Hydroxylase Isoform , 2003, Science.

[65]  Dae-Joong Kang,et al.  Bile salt biotransformations by human intestinal bacteria Published, JLR Papers in Press, November 18, 2005. , 2006, Journal of Lipid Research.

[66]  B. Wiedenmann,et al.  Escherichia coli Nissle 1917 Distinctively Modulates T-Cell Cycling and Expansion via Toll-Like Receptor 2 Signaling , 2005, Infection and Immunity.

[67]  M. Fujimiya,et al.  Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[68]  B. Patel.  Electroanalytical approaches to study signaling mechanisms in the gastrointestinal tract , 2011, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[69]  L. Kopp-Hoolihan,et al.  Prophylactic and therapeutic uses of probiotics: a review. , 2001, Journal of the American Dietetic Association.

[70]  S. Chrubasik,et al.  A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome , 2011, International Journal of Colorectal Disease.

[71]  Michael Schultz,et al.  Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. , 2008, Inflammatory Bowel Diseases.

[72]  P. Bork,et al.  A human gut microbial gene catalogue established by metagenomic sequencing , 2010, Nature.

[73]  B. Cukrowska,et al.  Specific Proliferative and Antibody Responses of Premature Infants to Intestinal Colonization with Nonpathogenic Probiotic E. coli Strain Nissle 1917 , 2002, Scandinavian journal of immunology.

[74]  N. Hyman,et al.  Serotonin and Its Role in Colonic Function and in Gastrointestinal Disorders , 2007, Diseases of the colon and rectum.

[75]  T. Selmer,et al.  Facile analysis of short-chain fatty acids as 4-nitrophenyl esters in complex anaerobic fermentation samples by high performance liquid chromatography. , 2011, Journal of chromatography. A.

[76]  B. de Las Rivas,et al.  Tyramine and Phenylethylamine Biosynthesis by Food Bacteria , 2012, Critical reviews in food science and nutrition.